Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Japan · Delayed Price · Currency is JPY

1,305.00

-17.00 (-1.29%)

Sep 11, 2026, 3:30 PM JST

Market Cap	54.33B -23.6%
Revenue (ttm)	33.92B +1.7%
Net Income	5.37B +6.1%
EPS	129.00 +6.1%
Shares Out	41.63M
PE Ratio	10.12
Forward PE	13.49
Dividend	50.00 (3.70%)
Ex-Dividend Date	Sep 29, 2026

Volume	114,200
Open	1,300.00
Previous Close	1,322.00
Day's Range	1,297.00 - 1,317.00
52-Week Range	1,067.00 - 2,005.00
Beta	-0.21
Analysts	Buy
Price Target	1,693.50 (+29.77%)
Earnings Date	Nov 10, 2026

About TYO:2395

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation... [Read more]

Industry Medical - Diagnostics & Research

Sector Healthcare

Founded 1957

Employees 1,680

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 2395

Full Company Profile

Financial Performance

In fiscal year 2026, TYO:2395's revenue was 32.52 billion, an increase of 0.34% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.27%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2395 stock is "Buy." The 12-month stock price target is ¥1,694, which is an increase of 29.77% from the latest price.

Price Target

¥1,694

(29.77% upside)

Analyst Consensus: Buy

Stock Forecasts